☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Early Breast Cancer
Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer
February 20, 2021
Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Brea...
September 20, 2020
Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in...
May 6, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.